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Abstract
The  focus  in  antioxidant  research  is  on
enzyme derivative investigations. Extracellu-
lar superoxide dismutase (EC-SOD) is of par-
ticular interest, as it demonstrates in vivo the
protective action against development of ath-
erosclerosis, hypertension, heart failure, dia-
betes  mellitus.  The  reliable  association  of
coronary artery disease with decreased level of
heparin-released EC-SOD was established in
clinical research. To create a base for and to
develop  antioxidant  therapy,  various  SOD
isozymes,  catalase  (CAT),  methods  of  gene
therapy,  and  combined  applications  of
enzymes are used. Covalent bienzyme SOD-
CHS-CAT  conjugate  (CHS,  chondroitin  sul-
phate) showed high efficacy and safety as the
drug candidate. There is an evident trend to
use the components of glycocalyx and extra-
cellular matrix for target delivery of medical
substances.  Development  of  new  enzyme
antioxidants  for  therapeutic  application  is
closely  connected  with  progress  in  medical
biotechnology,  the  pharmaceutical  industry,
and the bioeconomy.
Introduction
The high prevalence of cardiovascular dis-
eases has made them a constant focus of med-
ical  research.  Reperfusion  therapy  has
become  the  efficient  means  of  response  to
acute and threatening manifestations of car-
diovascular disorders. It is based on applica-
tion  of  thrombolytic  effect  and  stent  and/or
balloon  therapy  in  the  damaged  part  of  the
vascular bed. Such interventions proved to be
very efficient in restricting the size of acute
myocardial infarction (AMI), one of the most
serious lesions of the cardiovascular system.
The size of myocardial infarction is the princi-
pal  prognostic  factor  for  patients  with  AMI.
Reperfusion therapy itself can restrict the size
of AMI by up to 50% of the ischemic region.1
One in 4 patients with AMI has a lesion cover-
ing over 75% of the risk zone. It is thought that
left ventricle lesion that exceeds 20% reliably
confirms a prognosis of vulnerability in favor
of  severe  morbidity  and  mortality.  This
requires medical resources to reduce the size
of  AMI  from  the  fatal  75%  of  the  ischemic
region to 40% and under1 especially important
in the most serious cases. The known limita-
tion of reserves of reperfusion therapy justi-
fies the development of adjacent treatment2 to
help restrict the size of AMI and raise the sur-
vival  index  from  the  estimated  rate  of  0.25
(typical for use of reperfusion therapy only) to
0.60 and over.1
The role of oxidative stress in the develop-
ment of cardiovascular injuries has been reli-
ably  established.3,4 One  of  the  objectives  of
adjacent  (additional)  therapy  is  to  block  it.
Oxidative  stress  contributes  to  the  aggrava-
tion of disorders during thrombolysis for the
patency of the infarct-related artery (reperfu-
sion injury)5,6 and during vascular angioplasty
procedures  (development  of  restenosis).7,8
That is why it is important to search for high-
ly  efficient  resources  to  ensure  antioxidant
protection of the cardiovascular system.
Experimental and clinical
antioxidant research
Efficiency of antioxidant use in response to
the destructive action of oxidative stress was
shown in numerous experimental studies on
animals and human cells.9 Nevertheless, the
clinical trial data did not confirm their univer-
sal efficiency to be established in experimen-
tal research.10,11 Inconsistency of the clinical
results of testing antioxidants was explained
by  the  difference  between  the  models  of
lesions used on animals and cells from the
human body environment,1,5 by an incorrect
choice of the tested antioxidant, monitoring
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parameters of its activity, amount of the deriv-
ative doses injected, the duration of trials, and
patient selection criteria.9,11 New clinical trials
are,  therefore,  needed  and  strict  protocols
should  be  applied  with  a  wider  use  of  new
antioxidant derivatives. Given the well-known
lack of financial, organizational, scientific, and
medical resources, the future development of
antioxidant therapy could take two directions.
The first is related to the accurate, step-by-step
experimental and clinical research of various
antioxidants  to  gradually  collect  the  critical
mass of data on efficacy of antioxidant therapy
in response to the accumulated scepticism of
clinicians. The second is based on obtaining
clear and evident data of the medical efficien-
cy of antioxidants to promote a breakthrough
in practice methods and means of antioxidant
therapy.
Wide scope of antioxidant
research
Continuing  study  through  clinical  trials
seems  to  be  the  most  attractive  of  the  vast
range  of  ongoing  antioxidant  research.
Therefore,  edaravone  (3-methyl-1-phenyl-2-
pyrazoline-5-one) was used (intravenous infu-
sion  30  mg  during  10  min  within  6  h  after
manifestation  of  lesion  symptoms)  during
stenting of the arteries of patients with AMI
confirmed by angiography.12 It appeared that
edaravone  (compared  to  the  control
group/physiological solution) inhibited almost
all  the  manifestations  of  reperfusion  injury,
such as reperfusion arrhythmia, myocardium
stunning, fatal reperfusion injury. Edaravone
administration before reperfusion ensured a
smaller  area  of  AMI  by  enzyme  index  (area
under the curve of level of isozymes of creatine
kinase, e.g. CK-MB isoenzyme of the heart in
serum) and better clinical data.12 It should be
mentioned that just by inhibiting the reactive
oxygen forms which deplete the level of nitric
oxide  (NO),  edaravone  increased  the  blood-
flow  in  the  forearm  of  smokers,  acting  on
endothelium-related vascular dilatation.13 This
was also the target of co-enzyme Q10 action. It
ameliorated  bioenergetic  parameters,
increased the activity of extracellular superox-
ide-dismutase  (EC-SOD)  and  endothelium-
related dilatation after one month of oral dose
(300  mg  per  day)  in  patients  with  coronary
artery disease.14 Clinical trials of food (diet)
antioxidants  (vitamins  E,  C,  polyphenols,
carotenoids/lycopine,  beta-carotene,  co-
enzyme Q10) are ongoing, aimed at the preven-
tion  of  atherogenic  oxidation  of  low-density
lipoproteins and oxidative damage of endothe-
lium. This research is focused on evaluating
the influence on activity of transcription fac-
tors (with definition of polymorphisms of the
organism) and the development of individual
diets based on dietary antioxidants.15 Although
a huge amount of research into low-molecular
antioxidants  still  continues  to  be  published,
the volume of literature is decreasing. On such
a background, our attention is drawn to the
appearance  of  interesting  publications  dedi-




An increased amount of superoxide radical
(O-2) was noted in the arteries of spontaneous-
ly hypertensive rats; in this case genetic trans-
fer of EC-SOD ameliorated endothelium func-
tion  and  decreased  the  arterial  pressure.16
Thus, interaction of O-2 with NO should have
first place in extracellular space.17 Among all
antioxidant enzymes, only EC-SOD is localized
on the surface of the vascular lumen, interact-
ing with heparan sulphate proteoglycan, and
also  with  collagen18 and  fibulin-5,19 by  its
heparan-binding domain.10,17 EC-SOD is prob-
ably located along the whole depth of the vas-
cular  wall,  including  the  area  between
endothelium  and  vessel  muscle.20 Heparin
injection (in concentrations used for patients)
led  to  the  EC-SOD  bounded  earlier  by  the
endothelium  cells  and  other  tissues  to  be
released to the bloodflow.17,21 The antioxidant
effect of EC-SOD appears mainly on/into the
vascular  wall,  not  inside  the  volume  of  the
bloodflow.10,17 It was established that human
coronary artery diseases are reliably related to
the  decreased  level  of  heparin-released  EC-
SOD (131.0±42.8 ng/mL, P=0.0003 in the ath-
erosclerosis  group,  n=189,  and  156.9±66.2
ng/mL in control group, n=63).22,23 Its positive
correlation  with  the  level  of  high-density
lipoprotein  cholesterol  and  age  was  noted.23
The protective effect of EC-SOD is explained
by defence of vascular dilatator NO that is dif-
fusing from the endothelium cells to guanylat-
cyclase of the smooth muscle cells.10,17,24 This
was confirmed by the data received from the
model of high-volume hypertension in mice;
the 1-kidney-1-clamp model markedly induced
EC-SOD expression, whereas its activity was
increased  by  only  25%,  suggesting  a  partial
inactivation of EC-SOD in high-volume hyper-
tension.25 A decline in dilatation connected to
endothelium, increased arterial pressure and
oxidative stress of the vessels are noted among
wild-type  and  EC-SOD  knock-out  mice.
Recombinant  EC-SOD  decreased  the  arterial
pressure and ameliorated bioavailability of NO
in the aorta of wild-type mice and of EC-SOD
knock-out mice. This enzyme antioxidant did
not decrease the arterial pressure of knock-out
mice with blocked endothelium NO-synthase,
and of wild-type mice receiving NO-synthase
inhibitor. These results provided evidence of
the link between the vascular effect of recom-
binant  EC-SOD  and  the  NO-protection.25 In
line with other data,26-28the results also proved
the important role of this biocatalyst in cases
of hypertension. Similarly to the cases of ath-
erosclerosis10,17 and hypertension, the oxida-
tive stress and enzyme antioxidants play an
important role in the development of diabetes
mellitus  and  heart  failure.17 The  adhesive
properties  of  EC-SOD  were  used  to  obtain
recombinant SOD2/3.29 This SOD2/3 consisted
of  the  mature  human  mitochondrial  SOD-2
/Mn-SOD/  and  C-terminal  26-amino  acid
heparin-binding  tail from  EC-SOD  /SOD-3/.
The SOD2/3 was fully active and its tail was
responsible for enzyme affinity for endothelial
surface. Because of this, the SOD2/3 had anti-
inflammatory action against lung injury and




The notable interest of researchers in EC-
SOD,16,17,20-28 the tetramer of Cu,Zn-SOD with
a  high  affinity  to  heparan  sulphate31-33 in
mammals, or in its dimer form of Cu,Zn-SOD
with low affinity to heparan sulphate,16,31,33 in
rats led to the development of gene therapy
approaches  aimed  at  ensuring  antioxidant
activity of the organism due to transfer of the
appropriate genes.10,34 Antioxidant gene thera-
py  proved  to  be  successful  in  experimental
models of restenosis (rabbits, rats, pigs, etc.)
with  an  increase  in  expression  of  EC-SOD,
cytosolic  dimeric  Cu,Zn-SOD  (SOD-1),  cata-
lase (CAT), and hemoxygenase-1. This latter is
the enzyme induced by stress; it transforms
heme in biliverdin (for its further metabolic
transformation in bilirubin), CO and ions of
iron.34,35 The difficulties in the clinical use of
gene therapy are caused by the limited dura-
tion of transgenic expression, but cardiovascu-
lar  disorders  (e.g.,  atherosclerosis)  develop
over the decades, or, visa versa, occur sponta-
neously  (plaque  disruption,  thrombosis).
These factors make patient selection criteria
and the appropriate moment to start treatment
unclear. Development of efficient methods of
delivery of the gene material (limited trans-
duction  of  cardiovascular  cells),  immuno-
genecity of the used delivery systems, and dis-
tortion of redox status of cells required for nor-
mal signaling34 are also important problems.
Given these limitations, local delivery of gene
constructions seems to be the most efficient.
ReviewReview
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Endothelium denudation of rabbits with place-
ment of stent in the damaged area, with simul-
taneous catheter injection of adenovirus with
EC-SOD  code  (treatment  group)  or  of  beta-
galactosidase (control group) made it possible
to establish (according to monitoring vascular
histology, the level of reactive oxygen species
and  expression)  that  EC-SOD  significantly
accelerated  endothelium  restoration  and
decreased the size of neointimal thickening.36
Such  information  certainly  represents  local
gene  therapy  as  the  promising  strategy  of
response to the vessel lesions caused by artery
stenting.  Moreover,  EC-SOD  protein  concen-
tration in the hypertensive and normotensive
subjects are indistinguishable, whereas hyper-
tensive  patients  have  significantly  reduced
plasma EC-SOD activity.37 These data suggest
that this decrease in EC-SOD activity is not
due to a downregulation of the SOD-3 gene.
Meanwhile it should be also noted that poly-
morphism of the EC-SOD gene (for hyperten-
sion development in human) may also have an
important  role  in  patient  classification  and
possible gene therapy in future.
Superoxide dismutase and
catalase activity
The wide scope of research into antioxidant
protection  with  superoxide  dismutases17,21,31
also revealed the inactivation of endogenous
enzyme  by  hydrogen  peroxide.25 Prolonged
CAT  treatment  in  vivo (intravenous  bolus
injection of derivative of catalase-polyethylene
glycol for 3 days) decreased the blood pressure
of spontaneously hypertensive wild-type mice
(but not knock-out mice with bloked EC-SOD)
and  ameliorated  ex  vivo function  of  aorta
endothelium. These data clearly demonstrated
the central role of hydrogen peroxide in inacti-
vation  of  endogenous  EC-SOD.25,38 The  effi-
ciency of the decrease in hydrogen peroxide
level  in  cases  of  the  oxidative  stress  was
shown on the cell cultures. Overexpression of
CAT  protected  endothelium  of  human  aorta
against apoptosis caused by the oxidized forms
of low-density lipoproteins (oxLDL).39 Transfer
(in the smooth muscle cells of human aorta) of
SOD-1 and/or CAT genes inhibited the prolifer-
ation induced by oxLDL.40 Overexpression of
CAT or CAT together with SOD-1 in mice lack-
ing apolipoprotein E (ApoE-/-) inhibited devel-
opment  of  atherosclerosis  in  this  model
(lesion area/aortic tree, % of ApoE-/- mice with
overexpression: CAT 7.2±1.2, SOD-1 and CAT
5.3±0.7;  without  overexpression  21.0±3.4).41
Such results underlined the important role of
hydrogen peroxide in atherogenesis and the
need to protect against oxidative stress of the
vessels by simultaneous SOD- and CAT-activi-
ty. Such properties were combined in EUK-8,
the synthetic mimetic of SOD- and CAT-activi-
ty, containing Se and Mn. This derivative has
shown the protective effect (intra-abdominal
injections 25 mg/kg/day, three times a day for
four weeks) against remodeling of the left ven-
tricle  and  cardiac  decompensation  in  mice
with a model development of heart failure.42 In
the future, these results may provide the key
treatment for human heart failure; they con-
firm  the  efficacy  of  the  combined  effect  of
SOD- and CAT-activity in blocking the oxida-
tive stress. Meanwhile, the conjugation of SOD
or  CAT  with  antibody  to  platelet-endothelial
cell adhesion molecule-1 (PECAM-1) provided
a versatile molecular tool for testing the role of
reactive  oxygen  species  in  vascular  patholo-
gy.43 Anti-PECAM/SOD,  but  not  anti-
PECAM/CAT, inhibited a vascular endothelial
growth  factor  (VEGF)-induced  increase  in
endothelial permeability. This has identified a
key role for endogenous superoxide radical in
VEGF-mediated regulation of endothelial barri-
er function. On the contrary, anti-PECAM/CAT,
but not anti-PECAM/SOD, alleviated endothe-
lial  hyperpermeability,  implicating  primarily
hydrogen  peroxide  in  the  disruption  of  the
endothelial barrier. Targeting the antioxidant
enzymes  to  endothelial  cells  offers  a  future




The combined use of native forms of SOD
and CAT provided controversial data on antiox-
idant protection of the organism.10 The simul-
taneous action of SOD and CAT in the area of
lesion  development  was  required  to  demon-
strate the reliable effect of treatment as com-
pared to application of other compositions of
native or CHS modified SOD and CAT. It was
made possible by obtaining bienzyme conju-
gate, where SOD-1 was covalently bound via
glycosaminoglycan of the vascular wall, chon-
droitin  sulphate  (CHS),  with  CAT  (obtained
adduct was SOD-CHS-CAT covalent conjugate)
(Figure 1).44 Such conjugation contributed to
likening of SOD-1 to SOD-3 (since EC-SOD is
a glycoprotein),31-33 and the biochemically cou-
pled SOD- and CAT-activity is rendered in the
Figure 1. Antithrombotic effects of various combinations of superoxide dismutase (SOD)
and catalase (CAT) derivatives and SOD-CHS-CAT conjugate44 on (A) occlusion time and
(B) formed thrombus mass  in rat model of arterial thrombosis (intervals of effects are
shown as dark areas at the top of bars). 1, control; 2, SOD + CAT; 3, SOD + CHS + CAT;
4, SOD + (CAT-CHS); 5, (SOD-CHS) + CAT; 6, (SOD-CHS) + (CAT-CHS); 7, SOD-
CHS-CAT conjugate. Each combination was injected at the same dose of SOD (37±3 U)
and CAT (80±3 U) activity as the SOD-CHS-CAT conjugate. Each group of animals con-
sisted of 6 rats. Error values of the specific activity determination did not exceed 2-4%.Review
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received bienzyme derivative (when the prod-
uct of SOD reaction, hydrogen peroxide, is the
substrate for the following CAT transformation
in water and molecular oxygen being safe in
such  conditions.  Chemical  reactions  of  cat-
alyzed superoxide dismutase and catalase are:
On the model of arterial thrombosis in rats
induced by treatment of the vessel with satu-
rated  solution  of  ferrous  chloride,  the  bien-
zyme  conjugate  SOD-CHS-CAT  has  shown
antithrombotic effect in doses for two orders
less than for the mix of native SOD and CAT,
and for one order less than for the mix of SOD
and CAT modified by CHS. The SOD-CHS-CAT
conjugate had the optimal dose of anti-throm-
botic action (Figure 2). Cross-linking the pro-
teins with CHS allows the bienzyme conjugate
to be directed to the areas of vessel lesions. It
is well-known that the areas of atherosclerotic
lesions of the vascular wall are featured with
the increased content of CHS.10 Early intimal
thickening of the vascular wall in atherogene-
sis is also linked to accumulation of CHS.7
Chondroitin sulphate proteoglycan (CSPG)
was  observed  in  the  artery  sub-endothelium
after interventional procedure and stent place-
ment45 in atherosclerotic New Zealand white
rabbits. CSPG was the target for binding the
cationic liposomes (with prednisolone), con-
tributing to the reliable depression of growth
of intra-stent neointimae. These data provide
evidence for the possibility and efficiency of
using the components of vascular cell glycoca-
lyx  for  targeted  delivery  of  medical  sub-
stances.46 Moreover, glycocalyx of erythrocytes
may protect the tissue plasminogen activator
(tPA) bound with such biotin modified cells
against interaction with inhibitor of plasmino-
gen activator of type 1 (PAI-1), destroying the
local  electrostatic  interactions  between  tPA
and PAI-1, not disturbing the binding of tPA
with fibrin and plasminogen.47 Such stabiliza-
tion by glycocalyx makes it possible to offer
biotinilated  components  (tPA  and  erythro-
cytes), bounded via streptavidin, for thrombo-
sis prophylaxis in patients with high risk of
cerebral  or  vascular  lesion.48,49 The  noted
effects confirm the importance of a network of
distribution of coulomb charges during inter-
action with glycocalyx, and this may explain
the high efficiency of antithrombotic action of
bienzyme conjugate SOD-CHS-CAT. This deriv-
ative  does  not  disturb  the  hemodynamic
parameters of the rats and rabbits (blood pres-
sure and heart rate) and helps normalize them
after  hydrogen  peroxide  administration  in
vivo;50 it has acceptable indexes of acute toxi-
city  and  evident  antithrombotic  potential.10
The accumulated data contribute to the promo-





Scientific development of the new biophar-
maceutical  substances  (biopharmaceuticals)
implies the development of methods of medical
biotechnology, slowly but inevitably, becoming
the basis of the pharmaceutical industry. The
development  of  the  industry  is  based  on
progress  in  systems  biology  adding  to  the
knowledge and understanding of health pro-
tection, and contributing targeted work-out of
biopharmaceuticals.  The  development  of  the
Figure 2. The influence of bienzyme SOD-CHS-CAT conjugate in rat model of arterial
thrombosis10 (A) on occlusion time and (B) on obtained thrombus mass. Control rats
(with the same arterial injury) were injected normal saline instead of the bienzyme conju-
gate. The control values were assume to be 100%. Reverse magnitude of the thrombus
mass was used to provide a better demonstration (B). The SOD-CHS-CAT doses are given
as units of enzyme activity injected per rat.Review
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bioeconomy, the new model of economic activ-
ity, leads to the establishment of new types of
enterprise, and to new life for the companies
involved. The need to establish plants and fac-
tories  manufacturing  certified  bioreactives
(recombinant proteins, RNA, DNA, their frag-
ments, blood proteins, enzymes, peptides, vac-
cines,  etc.),  toxicology  centers,  and  the  cre-
ation of medical organizations for clinical tri-
als of bioderivatives, evidently limit the practi-
cal  use  of  biopharmaceuticals,  and  enzyme
antioxidants are of special interest. Such an
approach  requires  significant,  regular  and
adequate financial support. A balanced combi-
nation of the stages of scientific, pre-clinical,
biotechnological,  toxicological,  clinical,  and
technological developments is the pre-condi-
tion for the effective production of the medical
substances of the new generation. 
Conclusion
Oxidative stress is the peculiarity of all car-
diovascular diseases. Reactive oxygen species
may contribute to initiation and development
of  the  pathological  process.  Antioxidants
which are capable of blocking it, were efficient
in  experimental  works;  nevertheless,  data
from clinical trials appeared much more mod-
est. This led to scepticism about antioxidants
on the part of clinicians. An analysis of the lim-
itations in the clinical trials performed with
them leaves two ways open for development of
antioxidant therapy. The first is the accurate,
step-by-step research of antioxidants accord-
ing to strict, professionally designed trial pro-
tocols.  Many  reports  of  such  trials  are  still
being published; nevertheless their numbers
are decreasing with time. The second is to find
break-through  data  on  the  new  antioxidant
substances, thus accelerating the development
of  antioxidant  therapy.  The  spate  of  recent
publications  about  enzyme  antioxidants
encourages discussion about the next stage in
the development of antioxidant treatment. EC-
SOD is of important interest for researchers,
as it appeared to be the efficient marker and
corrector in cases of hypertension, heart fail-
ure,  diabetes  mellitus,  and  atherosclerosis.
The research into antioxidant efficacy of the
other enzymes with autonomic functions, such
as SOD-1, SOD-2, and CAT, continue; co-factor,
the reduced glutathione, is required for glu-
tathione peroxidase activity, and its quantity in
cases of oxidative stress is rather limited, thus
reducing its importance for medical purposes.
Methods of biological and chemical synthesis
are used to obtain the enzymes with connected
catalytic activity. Derivatives of this kind (such
as conjugate SOD-CHS-CAT) offer great prom-
ise  for  future  biopharmaceutical  research.
Nevertheless, the success of these derivatives
is the subject of efforts of specialists in various
disciplines,  while  the  actual  conditions  of
start-up and progress of medical biotechnology
and the pharmaceutical industry are important
steps for the bioeconomy. At the present time,
the  main  focus  in  trials  of  enzyme  antioxi-
dants is on scientific and pre-clinical stages of
this research.
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